Research Article

Study on the Potential Molecular Mechanism of Xihuang Pill in the Treatment of Pancreatic Cancer Based on Network Pharmacology and Bioinformatics

Jing Wang,1,2 Yaxing Zhang,3 Qiuyuan Wang,2,4 Luyao Wang,1,2 and Peitong Zhang1

1Guang Anmen Hospital, China Academy of Traditional Chinese Medicine, Beijing 100053, China
2Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China
3Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China
4Department of Orthopaedics, China-Japan Friendship Hospital, Beijing 100029, China

Correspondence should be addressed to Peitong Zhang; drzhangpeitong@hotmail.com

Received 14 December 2021; Revised 22 February 2022; Accepted 3 March 2022; Published 11 April 2022

Objective. We aimed to analyze the possible molecular mechanism of Xihuang pill (XHP) in the treatment of pancreatic cancer based on methods of network pharmacology, molecular docking, and bioinformatics. Methods. The main active components and targets were obtained through the TCMSP database, the BATMAN-TCM database, and the Chemistry database. The active ingredients were screened according to the “Absorption, Distribution, Metabolism, Excretion” (ADME) principle and supplemented with literature. We searched GeneCards, OMIM, TTD, and DrugBank databases for pancreatic cancer targets. The targets of disease and ingredients were intersected to obtain candidate key targets. Then, we constructed a protein-protein interaction (PPI) network for protein interaction analysis and a composition-key target map to obtain essential effective ingredients. Metascape was used to perform functional enrichment analysis to screen critical targets and pathways. The expression and prognosis of key targets were examined and analyzed, and molecular docking was carried out. Results. A total of 52 active ingredients of XHP, 121 candidate targets, and 52 intersecting targets were obtained. The core active ingredients of XHP for the treatment of pancreatic cancer were quercetin, 17-β-estradiol, ursolic acid, and daidzein. The core targets were EGFR, ESR1, MAPK1, MAPK8, MAPK14, TP53, and JUN, which were highly expressed genes of pancreatic cancer. Among them, EGFR and MAPK1 were significantly correlated with the survival of pancreatic cancer patients. The key pathway was the EGFR/MAPK pathway. The molecular docking results indicated that four active compositions had good binding ability to key targets. Conclusion. The molecular mechanism of XHP for the treatment of pancreatic cancer involved multiple components, multiple targets, and multiple pathways. This research theoretically elucidated the ameliorative effect of XHP against pancreatic cancer and might provide new ideas for further research on the treatment of pancreatic cancer.

1. Introduction

Pancreatic cancer is one of the most lethal malignant neoplasms, which causes over 331,000 deaths per year worldwide and ranks as the seventh most common cancer death [1]. Surgical resection with the addition of chemotherapy and radiotherapy plays an important role in the management of pancreatic cancer. Despite advances in chemotherapy, the overall 5-year survival rates ranged from 2% to 9% and remained relatively unchanged over the past several decades [2]. Therefore, new treatment strategies are needed for pancreatic cancer to achieve longer survival. Traditional Chinese medicine (TCM) has been applied clinically in China for more than a thousand years. As one of the most popular complementary and alternative medicine modalities in China, TCM has been gradually accepted due to its prominent efficacy and less toxicity.

Xihuang pill (XHP), as a famous TCM formula, has been used to clear heat, relieve toxicity, and expel stasis of blood since the Qing dynasty. It is composed of Niu Huang (Bovis...
2.1. Acquisition of Active Ingredients and Targets. The Traditional Chinese Medicine Systems Pharmacology Platform [13] (TCMSP) (https://tcmspw.com/tcmsp.php) was used to search the active ingredients of XHP. The filter criteria were oral bioavailability (OB) ≥ 30% and drug-likeness (DL) ≥ 0.18 according to the “Absorption, Distribution, Metabolism, and Excretion” (ADME) principle. Only when the ingredients in XHP met both of these two prerequisites were they considered as possible active ingredients of XHP. For the herbs in XHP whose information of active ingredients cannot be acquired from TCMSP database, they were screened in other authoritative websites such as BATMAN-TCM database [14] (http://bionet.ncpsb.org/batman-tcm/) and Chemistry database (http://www.organchem.csdb.cn). A literature search was also conducted to get supplements for the active ingredients of XHP which have been reported to have definite pharmacologic action for pancreatic cancer. The target information of the active ingredients was mainly acquired from the TCMSP database and was recorded by the DrugBank database [15, 16]. Then we accomplished the standardization of gene names and corresponding information search through the UniProt database [17] (https://www.uniprot.org/).

2.2. Gain the Targets of Pancreatic Cancer. We searched the keyword “pancreatic cancer” in GeneCards [18] (https://www.genecards.org/), Online Mendelian Inheritance in Man [19] (https://www.omim.org/), Therapeutic Target Database [20] (http://db.idrblab.net/ttd/), and DrugBank database (https://go.drugbank.com/) to comprehensively find relevant targets of pancreatic cancer. After getting the target information of pancreatic cancer, duplicate removal was conducted. Among them, the screening of the targets from the GenCards database was conducted according to the median of their relevance to pancreatic cancer.

2.3. Target Intersection Analysis. The R package “VennDiagram” was applied to map and intersect the targets of pancreatic cancer and targets of active ingredients in RStudio software, and the result was shown through a Venn diagram for a clear display.

2.4. PPI Network Construction. We employed the STRING [21] (https://string-db.org/) website to construct the PPI network analysis by choosing “multiple sequences” in function units and setting “Homo sapiens” as the organism specie with the interaction confidence retaining the acquisition value of 0.4. The result of the PPI network analysis was saved as a TSV document and was imported into Cytoscape 3.8.1 software. Then, the MCODE plug-in [22] was used for topology analysis to extract the key gene module. After obtaining the key genes, we found out the corresponding active ingredients of XHP and constructed the “composition-target” network diagram.

2.5. Enrichment Analysis. Metascape [23] (https://metascape.org/) was used for the gene enrichment analysis to get the function of the targets in the key gene module and to explore the biological process and corresponding pathways. Results were expressed as logP values, reflecting the significance of protein biological functions, and all results were considered significant at $P < 0.01$.

2.6. Expression and Survival Analysis of the Key Targets. GEPIA (Gene Expression Profiling Interactive Analysis) (http://gepia.cancer-pku.cn/) [24] is a database to take an overview of the profiles of the studied genes in different tumors. Here we used the database to investigate the different expression levels of every single key target in pancreatic cancer and normal tissue. The cutoff value of $\text{Log2FC} \geq 0.18$ according to the “Absorption, Distribution, Metabolism, and Excretion” principle was set to be 1, and the $p$ value cutoff value was set to 0.01. The KM plotter (https://kmplot.com/analysis/) [25] was employed to assess the prognostic value of different key targets, according to the gene expression in tumor samples of 177 patients with pancreatic cancer, the samples...
were divided into high expression group and low expression group for survival analysis. The Kaplan–Meier method was used to compare the survival data of the two groups. All the results were statistically significant when \( p < 0.05 \).

2.7. Molecular Docking. Molecular docking is a reliable approach for drug design based on the characteristics of receptors and the interaction between receptors and ligands, and ligands are typically drug molecules. We searched the 3D structures of the proteins corresponding to the key targets and used them as receptors for further docking. The ligands were the main active ingredients of XHP which we obtained after screening by the above methods, which were potentially effective for the treatment of pancreatic cancer. After that, CB-Dock (http://cao.labshare.cn/cb-dock/) [26] was used for molecular docking.

3. Results

Bezoar and musk have different main components due to different varieties, but it is not documented in detail in the TCMSP database, and musk is not recorded in the database. Therefore, we referred to relevant literature and databases to confirm the components of cultured bezoar in vitro and artificial musk in XHP sold commercially. Moreover, in the published literature, no pharmacological effect directly related to pancreatic cancer was collected in bezoar, musk, frankincense, and myrrh. In addition, the ingredients of XHP that did not meet the filter criteria in the TCMSP database were also included in this study because the related targets information of which in the database was linked to pancreatic cancer.

After normalization of the target names in the UniProt database and duplication omitting, there were 6 active ingredients and 24 related targets in bezoar, 6 active ingredients, and 55 related targets in musk. In frankincense, six active ingredients were identified, corresponding to 35 targets. We found 35 active ingredients and 93 corresponding targets in myrrh, respectively. After removing duplicates, we collected 52 active ingredients in the XHP and a total of 121 related target genes. Among them, bezoar contained CLRs (Mol ID: MOL000953) as same as musk. The results are presented in Table 1.

Through four consecutive screenings, 731 pancreatic cancer targets were identified in the GeneCards database. Other targets information obtained from the OMIM and TTD disease databases were combined, resulting in 1224 disease targets after removing duplicates. After Venn diagram analysis, 52 intersection targets between XHP and pancreatic cancer were finally confirmed (Figure 1). The results of interaction mapping of intersection target proteins constructed by the STRING database are shown in Figure 2. Nodes represent all proteins produced by a single gene locus, and lines represent proteins that collectively contribute to function, while the color of lines represents sources of evidence for drawing associations, such as purple for experimental validation, yellow for text mining, and black for coexpression among proteins.

We downloaded the interaction network in TSV files and imported it into Cytoscape software. An interactive network consisting of 52 points and 533 edges was obtained. The Mcode plug-in was utilized to acquire the key module. The Mcode is an algorithm that calculates the information of individual nodes in the network. The final module, obtained after processing according to the parameters of the nodes, is the key functional module in the interaction network. The results yielded a total of 27 key targets, which were ranked according to the degree value, as shown in Table 2.

An ingredient-key target network diagram was constructed in Cytoscape software, as shown in Figure 3. Nodes are for each target and ingredient, and lines represent correlations between nodes. The greater the degree value of a node, the darker the color, which indicates the degree of connectivity is greater. Therefore, the key active ingredients were quercetin, 17-\( \beta \)-estradiol, ursolic acid, and daidzein.

The Metascape platform is a gene functional annotation analysis tool that enables cognition of gene and protein function by applying bioinformatic analysis methods to analyze bulk genes and proteins. After importing the 27 potential key targets of XHP for pancreatic cancer into the Metascape platform, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis and gene ontology (GO) analysis were performed, respectively. The results of GO analysis included three sections: cellular components (CC), molecular functions (MF), and biological processes (BP). The cellular component result section reflects the location in the cell of the gene, the molecular function result section reflects the effect of a single gene product, and the biological process result section comprises various biological processes in which genes are involved, such as apoptosis and so on.

Further identification of the module yielded key functional modules (Figure 4). The module included EGFR, MAPK1, MAPK8, MAPK14, TP53, ESR1, and JUN genes. The enrichment analysis results were ranked according to LogP value, and the top 20 results were selected and presented as a bubble plot (Figure 5). The color of the bubbles from red to green represented the LogP value from small to large, and the larger the bubble is, the more genes are enriched in this pathway.

Finally, the cellular components of the genes involved in the vesicle lumen, membrane rafts, extracellular matrix, adherent junctions, the outer side of the plasma membrane, and so on. The molecular functions included cytokine receptor binding, heme binding, MAP kinase activity, serine-type endopeptidase activity, phosphatase binding, and so on. Biological processes involved positive regulation of cell migration, positive regulation of the MAPK cascade, positive regulation of protein serine/threonine kinase activity, response to hypoxia, and apoptosis. The biological pathways mainly included pathways in cancer, the MAPK signaling pathway, the NF-\( \kappa B \) signaling pathway, the JAK-STAT signaling pathway, and the IL-17 signaling pathway. Taking the MAPK signaling pathway as an example, the mechanism and potential targets of this pathway are shown in Figure 6. Yellow
nodes represent the enzymes or other compounds related to potential targets.

As shown in Figure 7 and Figure 8, compared with the expression of key targets in normal tissues, EGFR, ESR1, MAPK1, MAPK8, MAPK14, TP53, and JUN genes in pancreatic cancer were highly expressed. The expression differences of MAPK1, MAPK8, MAPK14, and TP53 were obvious, followed by EGFR and JUN, and the target with the

| Herb         | Mol ID     | Molecule name                                | Targets |
|--------------|------------|----------------------------------------------|---------|
| SHE XIANG    | MOL001232  | Testosterone                                 | 3       |
|              | MOL010919  | 17-Beta-estradiol                            | 38      |
|              | MOL000737  | Morin                                        | 6       |
|              | MOL002361  | Estragole                                    | 14      |
|              | MOL004783  | N-Nonane                                     | 2       |
|              | MOL00953   | Cholesterol                                  | 3       |
|              | MOL008838  | methyl(4R)-4-[(3R,5S,7S,8 R,9S,10S,12S,13 R,14S,17 R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoate | 2       |
|              | MOL008839  | Methyl desoxycholate                          | 3       |
|              | MOL008845  | Deoxycholic acid                             | 4       |
|              | MOL008846  | ZINC01280365                                 | 5       |
|              | MOL00953   | CLR                                          | 3       |
|              | MOL00511   | Ursolic acid                                 | 19      |
|              | MOL01215   | Tricaleol                                    | 2       |
|              | MOL01241   | O-acetyl-α-boswellic acid                    | 1       |
|              | MOL01243   | 3alpha-hydroxy-olean-12-en-24-oic-acid       | 6       |
|              | MOL01255   | Boswellic acid                               | 2       |
|              | MOL01295   | Phyllocadene                                 | 1       |
|              | MOL00390   | Daidzein                                     | 27      |
|              | MOL001001  | Quercetin-3-O-β-D-glucuronide                | 3       |
|              | MOL001002  | Ellagic acid                                 | 10      |
|              | MOL001004  | Pelargonidin                                 | 11      |
|              | MOL001006  | Poriferasta-7,22e-dien-3beta-ol              | 3       |
|              | MOL001009  | Guggulsterol-VI                              | 1       |
|              | MOL001013  | Mansumbinoic acid                            | 1       |
|              | MOL001026  | Myrranol C                                   | 4       |
|              | MOL001028  | (8R)-3-oxo-8-hydroxy-polypoda -13E,17 E,21-triene | 2       |
|              | MOL001029  | Myrrhanones B                                | 2       |
|              | MOL001031  | Epimansumbinol                               | 4       |
|              | MOL001033  | Diayangambin                                 | 5       |
|              | MOL001040  | (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl) chroman-4-one | 6       |
|              | MOL001045  | (13E,17 E,21E)-8-hydroxypolypodo-13,17,21-trien-3-one | 2       |
|              | MOL001046  | (13E,17 E,21E)-polypodo-13,17,21-triene-3,18-diol | 1       |
|              | MOL001049  | 16-Hydroperoxymansumbin-13(17)-en-3β-ol      | 2       |
|              | MOL001052  | Mansumbin-13(17)-en-3,16-dione                | 6       |
|              | MOL001061  | (16S, 20R)-dihydroxydammar-24-en-3-one       | 5       |
|              | MOL001062  | 15α-hydroxymansumbinone                      | 5       |
|              | MOL001063  | 28-Acetoxy-15α-hydroxymansumbinone           | 4       |
|              | MOL001095  | Isofuquierone                                | 2       |
|              | MOL001126  | [(5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,9-tetrahydroisobenzofuran-6,5-f] [1,3] | 16      |
|              | MOL001131  | Phellamurin_qt                               | 6       |
|              | MOL001138  | (3R,20S)-3,20-dihydroxydammar- 24-ene        | 6       |
|              | MOL001156  | 3-Methoxyfuranoguaia-9- en-8-one             | 9       |
|              | MOL001175  | Guggulsterone                                | 5       |
|              | MOL000358  | Beta-sitosterol                              | 21      |
|              | MOL000449  | Stigmastanol                                 | 23      |
|              | MOL000490  | Petumidin                                    | 7       |
|              | MOL000998  | Quercetin                                    | 55      |
|              | MOL000988  | 4,17(20)-(cis)-pregnadiene-3,16-dione        | 2       |
|              | MOL000996  | Guggulsterol IV                              | 3       |
|              | MOL001125  | Erlangerin B                                | 2       |
|              | MOL00127   | Erlangerin D                                | 7       |
|              | MOL00254   | Eugenol                                      | 25      |
|              | MOL000978  | Furaneudesma- 1,4-diene-6-one                | 11      |
least expression difference was ESR1. The Kaplan–Meier analysis showed that the expressions of EGFR, MAPK1, MAPK14, and TP53 were negatively correlated with survival time, while the expressions of ESR1, MAPK8, and JUN were positively correlated with survival time. Besides, there was no statistical significance in the results of ESR1, MAPK8, MAPK14, TP53, and JUN ($P > 0.05$).

In molecular docking, EGFR and MAPK1 were used as receptors, and the active ingredients, quercetin, 17-β-estradiol, ursolic acid, and daidzein, were used as ligands for docking to verify the potential active components and targets of XHP on pancreatic cancer (Table 3 and Figure 9).

The results indicated good binding ability, confirming the effectiveness and authenticity of the therapeutic components and targets.

### 4. Discussion

XHP has therapeutic effects on diverse tumors. It is widely used as a supplementary drug in the treatment of a variety of malignant tumors in China, such as pancreatic cancer [6], lung cancer [27], gastric cancer [28], and breast cancer [29]. However, the underlying mechanisms of XHP treating cancers remain unclear. Pancreatic cancer is a solid tumor...
with a very poor prognosis, and the treatment of which is still extremely difficult. Therefore, it is significant to find out the pharmacological mechanisms of XHP for the treatment of pancreatic cancer.

TCM is rooted in tens of centuries of clinical practices. Its curative effects are closely associated with the interaction of multiple ingredients, targets, and pathways. One of the difficulties in the pharmacological study of TCM is the numerous active components. Thus, network pharmacology has the advantage of searching for the key effective ingredients of traditional Chinese herbs, elucidating the regulation principles of complex molecules by constructing and establishing the systematic network of compound-protein and gene-disease [30].

In our present study, we applied the pharmacological method to predict and elucidate the potential molecular mechanisms of the action of XHP on pancreatic cancer. In the XHP active components and corresponding targets results, a total of 52 bioactive compounds and 121 targets in the XHP were obtained. There were 4 compounds including quercetin, ursolic acid, daidzein, and 17-beta-estradiol identified as the potential active ingredients of XHP, of which the biological activities against pancreatic cancer were reported previously [31]. For example, quercetin can inhibit the expression of the receptor for advanced glycation end products (RAGE), inhibit the PI3K/AKT/mTOR axis, regulate the death of pancreatic cancer cells, and increase the chemosensitivity of gemcitabine [32]. Ursolic acid also has an effect on increasing gemcitabine (GEM) chemosensitivity in pancreatic cancer cells possibly by triggering endoplasmic reticulum (ER) stress, activating apoptosis- and autophagy-related pathways, and decreasing the expression of RAGE [33]. In addition, an ex vivo assay shows that daidzein exhibits cytotoxic effects and genotoxic effects on human pancreatic cancer cell lines in a dose-dependent manner [34]. Besides, it is reported that the addition of β-estradiol with chemotherapeutic drugs increases chemosensitivity to pancreatic ductal adenocarcinoma [35]. Therefore, the abovementioned research studies indicate that many bioactive ingredients of XHP possess diverse effectiveness for treating pancreatic cancer.

The results of KEGG and GO enrichment analysis show that the therapeutic effect of the XHP in pancreatic cancer is mainly involved in the MAPK pathway, the NF-κB pathway, IL17 signaling, pathways in cancer, etc. These results are in agreement with other results suggesting that Integrin/EGFR-ERK/MAPK signaling promotes the growth and metastasis of pancreatic tumors [36]. Besides, the NF-κB pathway, as an important inflammatory mediator, is constitutively activated in pancreatic cancer and plays a crucial role in the development, progression, and drug resistance of pancreatic cancer [37]. IL17/IL17RA signaling is involved in pancreatic tumorigenesis, and IL17 blockade ameliorates PD-1 sensitivity [38].

Subsequently, the function gene module was identified through Metascape, which is a potential target module of XHP for pancreatic cancer. The gene module includes EGFR, ESR1, MAPK1, MAPK8, MAPK14, TP53, and JUN. The analysis results of the expression level verified that the key genes listed above were upregulated in pancreatic cancer.

Table 2: Key targets.

| Name     | Closeness centrality | Degree | Betweenness centrality |
|----------|----------------------|--------|------------------------|
| TP53     | 0.85                 | 42     | 0.068810131            |
| VEGFA    | 0.836065574          | 41     | 0.056756149            |
| IL6      | 0.796875             | 38     | 0.05317606             |
| MAPK1    | 0.796875             | 38     | 0.043544924            |
| EGF      | 0.784615385          | 37     | 0.037239889            |
| EGFR     | 0.784615385          | 37     | 0.043334685            |
| JUN      | 0.76119403           | 35     | 0.022646029            |
| MAPK8    | 0.76119403           | 35     | 0.024236994            |
| TNF      | 0.739130435          | 33     | 0.01515152             |
| ESR1     | 0.739130435          | 33     | 0.043118785            |
| PTGS2    | 0.739130435          | 33     | 0.013562229            |
| IL1B     | 0.728571429          | 32     | 0.012370454            |
| MMP2     | 0.718309859          | 31     | 0.010599301            |
| MAPK14   | 0.708333333          | 30     | 0.012303754            |
| CAT      | 0.698630137          | 30     | 0.007732274            |
| CCL2     | 0.708333333          | 30     | 0.017930964            |
| MMP1     | 0.662337662          | 26     | 0.016948756            |
| MMP3     | 0.662337662          | 26     | 0.016851676            |
| MPO      | 0.671052632          | 26     | 0.016505576            |
| IFNG     | 0.671052632          | 26     | 0.016541835            |
| NGF      | 0.662337662          | 25     | 0.00545143             |
| IL2      | 0.662337662          | 25     | 0.005095143            |
| CXCL12   | 0.653846154          | 25     | 0.004267719            |
| CCR2     | 0.6375               | 23     | 0.003965538            |
| HMOX1    | 0.64556962           | 23     | 0.00604897             |
| PLAU     | 0.62195122           | 21     | 0.001768495            |
| NOS2     | 0.593023256          | 17     | 7.63E-04               |
Figure 3: Composition-key target network diagram.

Figure 4: Key functional modules.
Figure 5: Continued.
**Figure 5: Continued.**

- MAP kinase activity
- Peroxidase activity
- Oxidoreductase activity
- Antioxidant activity
- Cytokine activity
- Cytokine receptor binding
- Metalloendopeptidase activity
- Serine-type endopeptidase activity
- Serine-type peptidase activity
- Serine hydrolase activity
- Phosphatase binding
- Receptor ligand activity
- Receptor regulator activity
- Ubiquitin protein ligase binding
- Cofactor binding
- Protein kinase activity

- Neuroinflammatory response
- Cellular response to reactive oxygen species
- Response to reactive oxygen species
- Response to mechanical stimulus
- Muscle cell proliferation
- Cellular response to oxidative stress
- Reactive oxygen species metabolic process
- Positive regulation of response to external stimulus
- Peptidyl-serine phosphorylation
- Cellular response to drug
- Response to oxidative stress
- Positive regulation of establishment of protein localization
- Positive regulation of cell proliferation
- Positive regulation of cell motility
- Positive regulation of cellular component movement
- Regulation of DNA-binding transcription factor activity
- Positive regulation of MAPK cascade
- Angiogenesis
- Blood vessel development

**Figure 5: Continued.**

- **(b)**

  - **(c)**

**Figure 5: Continued.**

- **(b)**

  - **(c)**
Figure 5: Functional enrichment bubble diagrams: (a) Go - CC diagram; (b) GO - MF diagram; (c) GO - BP diagram; (d) KEGG diagram.

Figure 6: MAPK signal pathway diagram.
samples compared with control samples. Further survival analysis of the Kaplan–Meier estimate showed that EGFR and MAPK1 were negatively correlated with survival time, which was statistically significant.

Furthermore, the molecular docking assay in this study showed that the four key active ingredients of XHP had good binding ability to key targets (EGFR and MAPK1). The CB-Dock website can predict the binding site of a given protein, calculate the center and size using a new curvature-based cavity detection method, and perform AutoDock Vina molecular docking. The lower the Vina score value, the higher the affinity between the receptor and the ligand. The docking results indicated that 17-beta-estradiol was verified the strongest binding activity with both EGFR and MAPK1 among the four potential key active ingredients.

Combining the enrichment and module analysis, the inhibition of the EGFR/MAPK pathway by XHP should be noted. EGFR is a transmembrane protein closely related to multiple pathological processes such as the proliferation, invasion, and metastasis of pancreatic cancer cells. Clinical studies have shown that the overexpression of EGFR could shorten the average overall survival rate of patients after PDAC resection and can be used as an independent predictor [39]. Accumulating evidence demonstrated that MAPK signaling promotes pathogenesis and biochemical progress of tumor cells [40]. MAPK cascades are substrates of activated EGFR. XHP could possibly inhibit EGFR and the downstream MAPK pathway.

High-throughput omics techniques, including proteomic and transcriptomic analysis, have enabled further comprehension of the TCM [41]. Though we predicted the possible targets by XHP by network pharmacology and molecular docking, the results are predictions after all. And for the next step, we intend to use XHP to treat pancreatic cancer both in vivo and in vitro experimental models, analyzing expression levels of protein and mRNA level by transcriptomics and proteomics studies.

Figure 7: Expression level of key targets.
Figure 8: Survival analysis of key targets.
5. Conclusion

In conclusion, this comprehensive network pharmacological analysis proposes numerous testable surmises about the potential molecular mechanisms of XHP formula for the treatment of pancreatic cancer and predicts that quercetin, 17-β-estradiol, ursolic acid, and daidzein are potential bioactive ingredients of XHP, which act on key genes such as EGFR and MAPK1 and regulate many pathways (EGFR/MAPK pathway, IL-17 signaling pathway, NF-κB pathway, pathways in cancer, etc.). It also should be noted that the XHP formula possibly exhibits an anti-tumor effect by regulating multiple biological pathways. The prediction results theoretically elucidated the ameliorative effect of XHP against pancreatic cancer and might facilitate further research on the mechanism of XHP or its bioactive compounds as an alternative therapy for pancreatic cancer.

Table 3: Docking results of key active ingredients and key targets.

|               | Quercetin Vina score | 17-Beta-estradiol Vina score | Ursolic acid Vina score | Daidzein Vina score |
|---------------|----------------------|-----------------------------|------------------------|--------------------|
| EGFR          | -8                   | -8.8                        | -8.3                   | -7.8               |
| MAPK1         | -8.5                 | -8.9                        | -8.8                   | -7.9               |

Figure 9: Docking modes: (a) EGFR-quercetin; (b) EGFR-17-beta-estradiol; (c) EGFR-ursolic acid; (d) EGFR-daidzein; (e) MAPK1-quercetin; (f) MAPK1-17-beta-estradiol; (g) MAPK1-ursolic acid; (h) MAPK1-daidzein.

5. Conclusion

In conclusion, this comprehensive network pharmacological analysis proposes numerous testable surmises about the potential molecular mechanisms of XHP formula for the treatment of pancreatic cancer and predicts that quercetin, 17-β-estradiol, ursolic acid, and daidzein are potential bioactive ingredients of XHP, which act on key genes such as EGFR and MAPK1 and regulate many pathways (EGFR/MAPK pathway, IL-17 signaling pathway, NF-κB pathway, pathways in cancer, etc.). It also should be noted that the XHP formula possibly exhibits an anti-tumor effect by regulating multiple biological pathways. The prediction results theoretically elucidated the ameliorative effect of XHP against pancreatic cancer and might facilitate further research on the mechanism of XHP or its bioactive compounds as an alternative therapy for pancreatic cancer.

Data Availability

All the data and materials used in the current study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] M. Ilic and I. Ilic, “Epidemiology of pancreatic cancer,” World Journal of Gastroenterology, vol. 22, no. 44, pp. 9694–9705, 2016.
[2] M. Sant, T. Aareleid, F. Berrino et al., “EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary,” Annals of Oncology, vol. 14, no. 5, pp. v61–v118, 2003.
[3] X. X. I. Xu Guo-shu and D.-X. Sun, “Effect of xihuang Pill combined with TC chemotherapy on clinical efficacy and quality of life of patients with advanced breast cancer,” Chinese journal of traditional Chinese medicine, vol. 36, no. 01, pp. 232–234, 2018.

[4] H. Yu, “Xihuang Pill combined with oxycodone hydrochloride sustained release tablets in the treatment of cancer pain and its effect on immune function and quality of life,” Chinese journal of traditional Chinese medicine, vol. 36, no. 05, pp. 1269–1271, 2018.

[5] Y. H. L. Wang, “Clinical study of Xihuang pill combined with letrozole in the treatment of advanced breast cancer,” Modern medicine & clinical, vol. 34, no. 02, pp. 429–433, 2019.

[6] J. Y. Zhang Ying and Y. Sun, “Clinical efficacy of xihuang pill combined with gemcitabine in patients with advanced pancreatic cancer,” Chinese patent medicine, vol. 32, no. 01, pp. 13–15, 2010.

[7] Q. Guo, “Review on the applications and molecular mechanisms of xihuang pill in tumor treatment. Evidence-based complementary and alternative medicine,” eCAM, vol. 2015, Article ID 854307, 2015.

[8] A. L. Hopkins, “Network pharmacology: the next paradigm in drug discovery,” Nature Chemical Biology, vol. 4, no. 11, pp. 682–690, 2008.

[9] S. Zhao and S. Li, “Network-based relating pharmacological and genomic spaces for drug target identification,” PLoS One, vol. 5, no. 7, Article ID e11764, 2010.

[10] S. Li, “Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae,” BMC Bioinformatics, vol. 11, no. Suppl 11, p. S6, 2010.

[11] J. E. Honts, “Evolving strategies for the incorporation of bioinformatic within the undergraduate cell biology curriculum,” Cell Biology Education, vol. 2, no. 4, pp. 233–247, 2003.

[12] C. Perez-Iratxeta, M. A. Andrade-Narvao, and J. D. Wren, “Evolving research trends in bioinformatics,” Briefings in Bioinformatics, vol. 8, no. 2, pp. 88–95, 2007.

[13] J. Ru, P. Li, J. Wang et al., “TCMS: a database of systems pharmacology for drug discovery from herbal medicines,” Journal of Cheminformatics, vol. 6, no. 1, p. 13, 2014.

[14] Z. Liu, F. Guo, Y. Wang et al., “BATMAN-TCM: a bioinformatics analysis tool for molecular mechanNism of traditional Chinese medicine,” Scientific Reports, vol. 6, no. 1, Article ID 21146, 2016.

[15] D. S. Wishart, C. Knox, A. C. Guo et al., “DrugBank: a knowledgebase for drugs, drug actions and drug targets,” Nucleic Acids Research, vol. 36, no. 1, pp. D901–D906, 2008.

[16] D. S. Wishart, Y. D. Feunang, A. C. Guo et al., “DrugBank 5.0: a major update to the DrugBank database for 2018,” Nucleic Acids Research, vol. 46, no. D1, pp. D1074–D1082, 2018.

[17] L. Breuza, “The UniProtKB guide to the human proteome,” Database: The Journal of Biological Databases and Curation, vol. 2016, 2016.

[18] G. Stelzer, N. Rosen, I. Plaschkes et al., “The GeneCards suite: from gene data mining to disease genome sequence analyses,” Current protocols in bioinformatics, vol. 54, pp. 1–33, 2016.

[19] J. S. Amberger and A. Hamosh, “Searching online mendelian inheritance in man (OMIM): a knowledgebase of human genes and genetic phenotypes,” Current protocols in bioinformatics, vol. 58, pp. 1–12, 2017.

[20] Y. Wang, S. Zhang, F. Li et al., “Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics,” Nucleic Acids Research, vol. 48, no. D1, pp. D1031–D1041, 2020.

[21] Y. Zhang, “A method for predicting protein complex in dynamic PPI networks,” BMC Bioinformatics, vol. 17, no. 7, p. 229, 2016.

[22] G. D. Bader and C. W. Hogue, “An automated method for finding molecular complexes in large protein interaction networks,” BMC Bioinformatics, vol. 4, no. 1, p. 2, 2003.

[23] Y. Zhou, B. Zhou, L. Pache et al., “Metascape provides a biologist-oriented resource for the analysis of systems-level datasets,” Nature Communications, vol. 10, no. 1, Article ID 1523, 2019.

[24] Z. Tang, C. Li, B. Kang, G. Gao, C. Li, and Z. Zhang, “GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses,” Nucleic Acids Research, vol. 45, pp. W1–W98, 2017.

[25] A. Nagy, G. Munkácsy, and B. Györffy, “Pancancer survival analysis of cancer hallmark genes,” Scientific Reports, vol. 11, no. 1, Article ID 6047, 2021.

[26] Y. Liu, M. Grimm, W.-t. Dai, M.-c. Hou, Z.-X. Xiao, and Y. Cao, “CB-Dock: a web server for cavity detection-guided protein-ligand blind docking,” Acta Pharmacologica Sinica, vol. 41, no. 1, pp. 138–144, 2020.

[27] J. Wang, D. Hou, Y. Peng, J. Xiong, and L. Xiong, “Efficacy and safety of Xihuang pill for lung cancer,” Medicine, vol. 99, no. 41, Article ID e22516, 2020.

[28] J. Wang, D. Hou, Y. Peng, J. Xiong, L. Xiong, and X. Tan, “Efficacy and safety of Xihuang pill for gastric cancer,” Medicine, vol. 100, no. 19, Article ID e25726, 2021.

[29] D. Mao, “Meta-analysis of xihuang pill efficacy when combined with chemotherapy for treatment of breast cancer. Evidence-based complementary and alternative medicine,” eCAM, vol. 2019, Article ID 3502460, 2019.

[30] X. Liu, “Network pharmacology-based approach to investigate the mechanisms of hedystis diffusa will. In the treatment of gastric cancer,” Evid Based Complement Altern Med, vol. 2018, Article ID 7802639, 2018.

[31] P. Asgharian, A. P. Tazehkand, S. R. Soofiyan et al., “Quercetin impact in pancreatic cancer: an overview on its therapeutic effects,” Oxidative Medicine and Cellular Longevity, vol. 2021, Article ID 4393266, 2021.

[32] C.-Y. Lan, S.-Y. Chen, C.-W. Kuo, C.-C. Lu, and G.-C. Yen, “Quercetin facilitates cell death and chemosensitivity through RAGE/P13K/akt/mTOR axis in human pancreatic cancer cells,” Journal of Food and Drug Analysis, vol. 27, no. 4, pp. 887–896, 2019.

[33] J. H. Lin, S. Y. Chen, C. C. Lu, A. A. Lin, and G. C. Yen, “Ursolic acid promotes apoptosis, autophagy, and chemosensitivity in gemcitabine-resistant human pancreatic cancer cells,” Phytotherapy Research, vol. 34, no. 8, pp. 2053–2066, 2020.

[34] G. Gundogdu, Y. Dodurga, M. Cetin, M. Secme, and B. Cicek, “The cytotoxic and genotoxic effects of daidzein on MIA PaCa-2 human pancreatic carcinoma cells and HT-29 human colon cancer cells,” Drug and Chemical Toxicology, vol. 43, no. 6, pp. 581–587, 2020.

[35] S. M. Akula, S. Candido, S. L. Abrams et al., “Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells,” Advances in biological regulation, vol. 75, Article ID 100672, 2020.

[36] W. Sheng, C. Chen, M. Dong et al., “Catecolicin promotes EGF-induced EMT in pancreatic cancer cells via Integrin/EGFR-ERK/MAPK signaling pathway,” Cell Death & Disease, vol. 8, no. 10, p. e3147, 2017.

[37] K. C. Pramanik, M. R. Makena, K. Bhowmick, and M. K. Pandey, “Advancement of NF-κB signaling pathway: a
novel target in pancreatic cancer," *International Journal of Molecular Sciences*, vol. 19, no. 12, 2018.

[38] Y. Zhang, V. Chandra, E. Riquelme Sanchez et al., "Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer," *Journal of Experimental Medicine*, vol. 217, no. 12, 2020.

[39] J. B. Fagman, D. Ljungman, P. Falk et al., "EGFR, but not COX-2, protein in resected pancreatic ductal adenocarcinoma is associated with poor survival," *Oncology Letters*, vol. 17, no. 6, pp. 5361–5368, 2019.

[40] S. Lee, J. Rauch, and W. Kolch, "Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity," *International Journal of Molecular Sciences*, vol. 21, no. 3, 2020.

[41] J. Liang, X. Deng, F.-S. Wu, and Y.-F. Tang, "Transcriptomic and proteomic analysis of human hepatic stellate cells treated with natural taurine," *Molecular Medicine Reports*, vol. 7, no. 5, pp. 1442–1452, 2013.